Abstract
Generally considered indolent, ovarian tumors of low malignant potential (LMP) have a small but finite risk of aggressive behavior. There is controversy surrounding the management of both the indolent and aggressive variants of ovarian LMP tumors. This review will explore the recent advances in the understanding of the genetic composition, pathologic differences and controversies in clinical management of this unique group of ovarian tumors.